<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.cancernetwork.com/view/a-new-era-of-personalized-cancer-therapeutics-at-esmo</loc>
      <lastmod>2026-11-19T19:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T19:00:00Z</news:publication_date>
        <news:title><![CDATA[A New Era of Personalized Cancer Therapeutics at ESMO]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/fda-grants-priority-review-to-sonesitatug-vedotin-in-pretreated-cldn18-2-gastric-gej-cancers</loc>
      <lastmod>2026-11-19T15:45:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T15:45:00Z</news:publication_date>
        <news:title><![CDATA[FDA Grants Priority Review to Sonesitatug Vedotin in Pretreated CLDN18.2+ Gastric/GEJ Cancers]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/bellwave-program-for-nemtabrutinib-discontinued-after-phase-3-cll-sll-trial</loc>
      <lastmod>2026-11-19T15:30:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T15:30:00Z</news:publication_date>
        <news:title><![CDATA[BELLWAVE Program for Nemtabrutinib Discontinued After Phase 3 CLL/SLL Trial]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/et-adherence-raises-cardiometabolic-risk-improves-survival-in-hr-breast-cancer</loc>
      <lastmod>2026-11-19T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T15:00:00Z</news:publication_date>
        <news:title><![CDATA[ET Adherence Raises Cardiometabolic Risk, Improves Survival in HR+ Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/bhv-1530-shows-responses-in-fgfr3-altered-urothelial-and-head-and-neck-cancers</loc>
      <lastmod>2026-11-19T14:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T14:00:00Z</news:publication_date>
        <news:title><![CDATA[BHV-1530 Shows Responses in FGFR3-Altered Urothelial and Head and Neck Cancers]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/ascent-04-sacituzumab-govitecan-plus-pembrolizumab-in-first-line-pd-l1-positive-metastatic-tnbc</loc>
      <lastmod>2026-11-19T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:05:00Z</news:publication_date>
        <news:title><![CDATA[ASCENT-04: Sacituzumab Govitecan Plus Pembrolizumab in First-Line PD-L1–Positive Metastatic TNBC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/clinical-scenario-treatment-selection-at-first-relapse-in-multiple-myeloma</loc>
      <lastmod>2026-11-19T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Clinical Scenario: Treatment Selection at First Relapse in Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/clinical-scenario-celmod-selection-after-car-t-cell-and-bispecific-antibody-therapy-in-multiple-myeloma</loc>
      <lastmod>2026-11-19T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Clinical Scenario: CELMoD Selection After CAR T-Cell and Bispecific Antibody Therapy in Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/ascent-03-and-tropion-breast02-comparing-adc-efficacy-safety-and-treatment-considerations-in-metastatic-tnbc</loc>
      <lastmod>2026-11-19T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:00:00Z</news:publication_date>
        <news:title><![CDATA[ASCENT-03 and TROPION-Breast02: Comparing ADC Efficacy, Safety, and Treatment Considerations in Metastatic TNBC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/positioning-celmods-alongside-car-t-cell-therapy-and-bispecific-antibodies-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-19T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Positioning CELMoDs Alongside CAR T-Cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/recognizing-menin-inhibitor-differentiation-syndrome-as-an-aml-class-effect</loc>
      <lastmod>2026-11-19T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Recognizing Menin Inhibitor Differentiation Syndrome as an AML Class Effect]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/clinical-scenario-celmod-selection-before-car-t-cell-therapy-in-multiple-myeloma</loc>
      <lastmod>2026-11-19T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Clinical Scenario: CELMoD Selection Before CAR T-Cell Therapy in Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/sno-2026-shows-lasting-responses-ongoing-research-for-safusidenib</loc>
      <lastmod>2026-11-18T22:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T22:00:00Z</news:publication_date>
        <news:title><![CDATA[SNO 2026 Shows Lasting Responses, Ongoing Research for Safusidenib]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/how-should-car-t-and-bispecifics-be-sequenced-in-multiple-myeloma-</loc>
      <lastmod>2026-11-18T21:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T21:00:00Z</news:publication_date>
        <news:title><![CDATA[How Should CAR T and Bispecifics Be Sequenced in Multiple Myeloma?]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/why-car-t-may-belong-before-bispecifics-in-multiple-myeloma</loc>
      <lastmod>2026-11-18T19:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Why CAR T May Belong Before Bispecifics in Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/celmods-vs-t-cell-redirecting-therapies-at-first-relapse-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.415Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.415Z</news:publication_date>
        <news:title><![CDATA[CELMoDs vs T-Cell-Redirecting Therapies at First Relapse in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/evaluating-class-level-and-agent-level-differences-among-celmods-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.415Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.415Z</news:publication_date>
        <news:title><![CDATA[Evaluating Class-Level and Agent-Level Differences Among CELMoDs in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/balancing-treatment-sequencing-and-patient-needs-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.415Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.415Z</news:publication_date>
        <news:title><![CDATA[Balancing Treatment Sequencing and Patient Needs in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/disease-biology-vs-patient-context-selecting-treatment-at-first-relapse-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.415Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.415Z</news:publication_date>
        <news:title><![CDATA[Disease Biology vs Patient Context: Selecting Treatment at First Relapse in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/case-based-discussion-treatment-selection-for-biochemical-first-relapse-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.415Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.415Z</news:publication_date>
        <news:title><![CDATA[Case-Based Discussion: Treatment Selection for Biochemical First Relapse in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/applying-celmod-class-level-and-agent-level-evidence-to-treatment-selection-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.415Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.415Z</news:publication_date>
        <news:title><![CDATA[Applying CELMoD Class-Level and Agent-Level Evidence to Treatment Selection in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/sequencing-celmods-and-prioritizing-current-treatment-needs-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.415Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.415Z</news:publication_date>
        <news:title><![CDATA[Sequencing CELMoDs and Prioritizing Current Treatment Needs in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/comparing-celmod-treatment-strategies-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.414Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.414Z</news:publication_date>
        <news:title><![CDATA[Comparing CELMoD Treatment Strategies in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/sequencing-celmods-and-integrating-treatment-strategies-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.414Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.414Z</news:publication_date>
        <news:title><![CDATA[Sequencing CELMoDs and Integrating Treatment Strategies in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/safety-considerations-and-treatment-selection-for-celmods-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.414Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.414Z</news:publication_date>
        <news:title><![CDATA[Safety Considerations and Treatment Selection for CELMoDs in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/successor-2-and-mezigdomide-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.414Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.414Z</news:publication_date>
        <news:title><![CDATA[SUCCESSOR-2 and Mezigdomide in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/patient-selection-and-sequencing-of-celmods-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.414Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.414Z</news:publication_date>
        <news:title><![CDATA[Patient Selection and Sequencing of CELMoDs in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/interpreting-mrd-negative-responses-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.414Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.414Z</news:publication_date>
        <news:title><![CDATA[Interpreting MRD-Negative Responses in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/cemsidomide-emerging-evidence-and-safety-management-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-18T18:42:29.414Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:42:29.414Z</news:publication_date>
        <news:title><![CDATA[Cemsidomide: Emerging Evidence and Safety Management in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/liso-cel-combo-shows-deep-durable-responses-in-relapsed-refractory-cll-sll</loc>
      <lastmod>2026-11-18T18:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Liso-Cel Combo Shows Deep, Durable Responses in Relapsed/Refractory CLL/SLL]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/fda-accepts-snda-for-selinexor-ruxolitinib-in-myelofibrosis</loc>
      <lastmod>2026-11-18T17:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T17:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Accepts sNDA for Selinexor/Ruxolitinib in Myelofibrosis]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/pre-sbrt-ctdna-linked-to-earlier-progression-in-oligoprogressive-crpc</loc>
      <lastmod>2026-11-18T16:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Pre-SBRT ctDNA Linked to Earlier Progression in Oligoprogressive CRPC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/galinpepimut-s-improves-overall-survival-in-phase-3-aml-maintenance-trial</loc>
      <lastmod>2026-11-18T15:30:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T15:30:00Z</news:publication_date>
        <news:title><![CDATA[Galinpepimut-S Improves Overall Survival in Phase 3 AML Maintenance Trial]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/theranostics-moves-upfront-a-new-chapter-for-radiopharmaceutical-therapy</loc>
      <lastmod>2026-11-18T15:12:36.868Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T15:12:36.868Z</news:publication_date>
        <news:title><![CDATA[Theranostics Moves Upfront: A New Chapter for Radiopharmaceutical Therapy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/paradigm-supports-venetoclax-azacitidine-in-select-fit-aml-populations</loc>
      <lastmod>2026-11-18T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T15:00:00Z</news:publication_date>
        <news:title><![CDATA[PARADIGM Supports Venetoclax/Azacitidine in Select Fit AML Populations]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/gedatolisib-joins-a-biomarker-driven-second-line-algorithm-in-hr-her2-mbc</loc>
      <lastmod>2026-11-18T14:54:34.834Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:54:34.834Z</news:publication_date>
        <news:title><![CDATA[Gedatolisib Joins a Biomarker-Driven Second-Line Algorithm in HR+/HER2– mBC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/3-patient-profiles-adc-therapy-in-tnbc</loc>
      <lastmod>2026-11-18T14:46:51.208Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:46:51.208Z</news:publication_date>
        <news:title><![CDATA[3 Patient Profiles: ADC Therapy in TNBC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/3-things-you-should-know-about-met-altered-nsclc</loc>
      <lastmod>2026-11-18T14:36:48.239Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:36:48.239Z</news:publication_date>
        <news:title><![CDATA[3 Things You Should Know About MET-Altered NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/advances-in-hematologic-oncology-reflections-from-the-soho-2026-annual-meeting</loc>
      <lastmod>2026-11-18T14:18:25.054Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:18:25.054Z</news:publication_date>
        <news:title><![CDATA[Advances in Hematologic Oncology: Reflections from the SOHO 2026 Annual Meeting]]></news:title>
      </news:news>
	</url></urlset>